NCT02604563 Aging, Geriatric Syndromes and Clonal Hematopoiesis
| NCT ID | NCT02604563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Geriatrics |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2016-03-10 |
| Primary Completion | 2030-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2016-03-10 with a primary completion date of 2030-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone.
Eligibility Criteria
Inclusion Criteria: * At least 50 years of age. * Able to understand written and spoken English. * Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort) Exclusion Criteria: * Inability or unwillingness to complete health questionnaire (with the exception of hip replacement participants). * History of a recent (\<30 days) acute viral illness. * Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy \> 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment. * Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease. * Vulnerable populations (e.g. prisoners). * Known infection with Hepatitis B or C, HTLV, or HIV. * Additional exclusion for optional bone marrow aspirate/biopsy substudy: * Use of medications for anticoagulation or "blood thinning" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban) * allergy to lidocaine or other local anesthetics.
Contact & Investigator
Meagan Jacoby, M.D.
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT02604563 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Geriatrics. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02604563 currently recruiting?
Yes, NCT02604563 is actively recruiting participants. Contact the research team at mjacoby@wustl.edu for enrollment information.
Where is the NCT02604563 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT02604563 clinical trial?
NCT02604563 is sponsored by Washington University School of Medicine. The principal investigator is Meagan Jacoby, M.D. at Washington University School of Medicine. The trial plans to enroll 2,000 participants.